• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV 可变环中和表位的跨株保守性比较。

Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes.

机构信息

Department of Pharmacology, New York University School of Medicine, New York, New York, United States of America.

出版信息

PLoS One. 2010 Dec 29;5(12):e15994. doi: 10.1371/journal.pone.0015994.

DOI:10.1371/journal.pone.0015994
PMID:21209919
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3012121/
Abstract

Although the sequence variable loops of the human immunodeficiency virus' (HIV-1) surface envelope glycoprotein (gp120) can exhibit good immunogenicity, characterizing conserved (invariant) cross-strain neutralization epitopes within these loops has proven difficult. We recently developed a method to derive sensitive and specific signature motifs for the three-dimensional (3D) shapes of the HIV-1 neutralization epitopes in the third variable (V3) loop of gp120 that are recognized by human monoclonal antibodies (mAbs). We used the signature motif method to estimate the conservation of these epitopes across circulating worldwide HIV-1 strains. The epitope targeted by the anti-V3 loop neutralizing mAb 3074 is present in 87% of circulating strains, distributed nearly evenly among all subtypes. The results for other anti-V3 Abs are: 3791, present in 63% of primarily non-B subtypes; 2219, present in 56% of strains across all subtypes; 2557, present in 52% across all subtypes; 447-52D, present in 11% of primarily subtype B strains; 537-10D, present in 9% of primarily subtype B strains; and 268-D, present in 5% of primarily subtype B strains. The estimates correlate with in vitro tests of these mAbs against diverse viral panels. The mAb 3074 thus targets an epitope that is nearly completely conserved among circulating HIV-1 strains, demonstrating the presence of an invariant structure hidden in the dynamic and sequence-variable V3 loop in gp120. Since some variable loop regions are naturally immunogenic, designing immunogens to mimic their conserved epitopes may be a promising vaccine discovery approach. Our results suggest one way to quantify and compare the magnitude of the conservation.

摘要

虽然人类免疫缺陷病毒(HIV-1)表面包膜糖蛋白(gp120)的序列可变环可表现出良好的免疫原性,但鉴定这些环内保守(不变)的跨株中和表位一直很困难。我们最近开发了一种方法,可以从三维(3D)形状推导 gp120 第三可变环(V3 环)中 HIV-1 中和表位的敏感和特异性特征基序,这些表位由人类单克隆抗体(mAb)识别。我们使用特征基序方法来估计这些表位在全球循环 HIV-1 株中的保守性。抗 V3 环中和 mAb 3074 靶向的表位存在于 87%的循环株中,几乎均匀分布于所有亚型中。其他抗 V3 Abs 的结果为:3791,存在于主要是非 B 亚型的 63%中;2219,存在于所有亚型的 56%中;2557,存在于所有亚型的 52%中;447-52D,存在于主要是 B 亚型的 11%中;537-10D,存在于主要是 B 亚型的 9%中;268-D,存在于主要是 B 亚型的 5%中。这些估计与这些 mAb 对各种病毒面板的体外测试相关。因此,mAb 3074 靶向一个几乎完全存在于循环 HIV-1 株中的表位,证明了在 gp120 的动态和序列可变 V3 环中隐藏着一个不变的结构。由于一些可变环区域具有天然的免疫原性,设计模拟其保守表位的免疫原可能是一种很有前途的疫苗发现方法。我们的结果表明了一种量化和比较保守性程度的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e2a/3012121/30ffba442b2b/pone.0015994.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e2a/3012121/25a0c3870c1f/pone.0015994.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e2a/3012121/ddd35ce89a3e/pone.0015994.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e2a/3012121/30ffba442b2b/pone.0015994.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e2a/3012121/25a0c3870c1f/pone.0015994.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e2a/3012121/ddd35ce89a3e/pone.0015994.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e2a/3012121/30ffba442b2b/pone.0015994.g003.jpg

相似文献

1
Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes.HIV 可变环中和表位的跨株保守性比较。
PLoS One. 2010 Dec 29;5(12):e15994. doi: 10.1371/journal.pone.0015994.
2
Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.人类抗V3单克隆抗体识别的1型人类免疫缺陷病毒表位的全球分布情况。
AIDS Res Hum Retroviruses. 2009 Apr;25(4):441-50. doi: 10.1089/aid.2008.0188.
3
Quantitative assessment of masking of neutralization epitopes in HIV-1.HIV-1 中和表位掩蔽的定量评估。
Vaccine. 2011 Sep 9;29(39):6736-41. doi: 10.1016/j.vaccine.2010.12.052. Epub 2011 Jan 7.
4
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.在CCR5限制性而非CXCR4利用型的原发性人类免疫缺陷病毒1型毒株的天然包膜糖蛋白寡聚体中,一个保守的、CD4诱导性V3环中和表位的隐秘性质。
J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005.
5
Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.兔抗 HIV-1 gp120 第三可变环(V3)区抗体结构揭示抗原表位复杂度增加与抗体亲和力成熟及新结合模式的相关性。
J Virol. 2018 Mar 14;92(7). doi: 10.1128/JVI.01894-17. Print 2018 Apr 1.
6
Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.计算预测靶向人类抗 V3 HIV 单克隆抗体的中和表位。
PLoS One. 2014 Feb 25;9(2):e89987. doi: 10.1371/journal.pone.0089987. eCollection 2014.
7
Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.能够呈现HIV-1 V3环冠部且构象适合产生447-52D样抗体的免疫原的设计。
Biochem J. 2006 Nov 1;399(3):483-91. doi: 10.1042/BJ20060588.
8
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.一种人源单克隆抗体的跨亚型中和活性由1型人类免疫缺陷病毒的GPGR V3基序决定。
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254.
9
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.对V3构象敏感表位具有特异性的人源单克隆抗体可中和来自不同进化枝的1型人类免疫缺陷病毒原始分离株。
J Virol. 2002 Sep;76(18):9035-45. doi: 10.1128/jvi.76.18.9035-9045.2002.
10
A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.一种新型抗人免疫缺陷病毒1型gp120的人源抗体依赖于V1、V2和V3环,并有助于界定广泛中和抗体免疫球蛋白G1 b12的表位。
J Virol. 2003 Jun;77(12):6965-78. doi: 10.1128/jvi.77.12.6965-6978.2003.

引用本文的文献

1
Structural basis of transmembrane coupling of the HIV-1 envelope glycoprotein.HIV-1 包膜糖蛋白跨膜偶联的结构基础。
Nat Commun. 2020 May 8;11(1):2317. doi: 10.1038/s41467-020-16165-0.
2
Structure of the membrane proximal external region of HIV-1 envelope glycoprotein.HIV-1 包膜糖蛋白膜近端外部区域的结构。
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8892-E8899. doi: 10.1073/pnas.1807259115. Epub 2018 Sep 5.
3
Structural basis for membrane anchoring of HIV-1 envelope spike.HIV-1包膜刺突膜锚定的结构基础。

本文引用的文献

1
Conserved structural elements in the V3 crown of HIV-1 gp120.HIV-1 gp120 V3 冠部的保守结构元件。
Nat Struct Mol Biol. 2010 Aug;17(8):955-61. doi: 10.1038/nsmb.1861. Epub 2010 Jul 11.
2
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.抗 V3 单克隆抗体对多种 HIV-1 亚型表现出广泛的中和活性。
PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254.
3
Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.
Science. 2016 Jul 8;353(6295):172-175. doi: 10.1126/science.aaf7066. Epub 2016 Jun 23.
4
Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.预融合HIV-1包膜三聚体与四级结构特异性抗体复合物的免疫原性
J Virol. 2015 Dec 30;90(6):2740-55. doi: 10.1128/JVI.02380-15.
5
Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.鉴定HIV-1 gp120可变区2和3环中与α4β7整合素受体结合的新区域。
PLoS One. 2015 Dec 1;10(12):e0143895. doi: 10.1371/journal.pone.0143895. eCollection 2015.
6
Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure.稳定的、未裂解的HIV-1包膜糖蛋白gp140形成具有天然样结构的紧密折叠三聚体。
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18542-7. doi: 10.1073/pnas.1422269112. Epub 2014 Dec 15.
7
Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?使用AIDSVAX免疫原进行疫苗接种会导致人类受试者体内HIV感染的抗体依赖性增强吗?
Hum Vaccin Immunother. 2014;10(10):3013-6. doi: 10.4161/21645515.2014.972148. Epub 2014 Nov 21.
8
Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.通过冷冻电子断层扫描在完整病毒上可视化逆转录病毒包膜刺突与V3环抗体447-52D的复合物。
J Virol. 2014 Nov;88(21):12265-75. doi: 10.1128/JVI.01596-14. Epub 2014 Aug 13.
9
Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.针对HIV-1 gp120可变环表位的交叉亚型疫苗。
Vaccine. 2014 Sep 3;32(39):4916-24. doi: 10.1016/j.vaccine.2014.07.026. Epub 2014 Jul 18.
10
Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.计算预测靶向人类抗 V3 HIV 单克隆抗体的中和表位。
PLoS One. 2014 Feb 25;9(2):e89987. doi: 10.1371/journal.pone.0089987. eCollection 2014.
结构基础上的交叉反应的基因相关的人类抗 hiv-1 mabs: implications for design 的 v3 为基础的免疫原。
Structure. 2009 Nov 11;17(11):1538-46. doi: 10.1016/j.str.2009.09.012.
4
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.通过将免疫反应聚焦于一个中和表位在兔体内诱导产生的针对HIV-1的跨亚型中和抗体。
Virology. 2009 Sep 15;392(1):82-93. doi: 10.1016/j.virol.2009.05.039. Epub 2009 Jul 26.
5
Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.人类抗V3单克隆抗体识别的1型人类免疫缺陷病毒表位的全球分布情况。
AIDS Res Hum Retroviruses. 2009 Apr;25(4):441-50. doi: 10.1089/aid.2008.0188.
6
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.从HIV感染个体的记忆B细胞中分离出的中和抗体具有广泛的多样性。
Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.
7
Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.猕猴模型中使用抗HIV-1的人源中和单克隆抗体进行被动免疫:实验方法
Methods Mol Biol. 2009;525:559-66, xiv. doi: 10.1007/978-1-59745-554-1_31.
8
Challenges in the development of an HIV-1 vaccine.人类免疫缺陷病毒1型疫苗研发中的挑战。
Nature. 2008 Oct 2;455(7213):613-9. doi: 10.1038/nature07352.
9
Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.可溶性CD4拓宽了针对HIV-1 B亚型和C亚型参考病毒的V3定向单克隆抗体和豚鼠疫苗血清的中和作用。
Virology. 2008 Oct 25;380(2):285-95. doi: 10.1016/j.virol.2008.07.007. Epub 2008 Sep 18.
10
Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.将免疫反应聚焦于HIV-1 gp120包膜的中和表位V3环。
Virology. 2008 Mar 15;372(2):233-46. doi: 10.1016/j.virol.2007.09.024. Epub 2007 Dec 3.